1,033 results on '"Morra, Enrica"'
Search Results
202. Zap-70 EXPRESSION and Igvh Mutational Status as Markers for Gene EXPRESSION Signature IN B-CLL PATIENTS for Prognostic Classification.
203. Evaluation of the Impact of Three Different Pre-Transplant Strategies On the Outcome of Myeloma Patients Candidates to High-Dose Therapy.
204. Positive Direct Antiglobulin Test (DAT) in Chronic Lymphocytic Leukemia (CLL) Patients: Correlation with Prognostic Factors.
205. Interferon alpha-2b as therapy for patients with Ph‘-positive chronic myelogenous leukemia
206. Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes
207. Multiple myeloma associated to HIV infection: report of two patients
208. Bone marrow and blood involvement by non-Hodgkin's lymphoma: A study of clinicopathologic correlations and prognostic significance in relationship to the Working Formulation
209. Fludarabine-Based Combination Therapies for Waldenström's Macroglobulinemia
210. Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia
211. Radiofrequency ablation of hepatic Hodgkin lymphoma
212. Front-Line Chemo-Immunotherapy Rituximab-FC + Rituximab Maintenance in Patients with Untreated Advanced Stage Non Follicular Lymphoma (INFL): Preliminary Results of a Prospective Study of the Intergruppo Italiano Linfomi and Roche (ML18324).
213. Reinforced Mini-BEAM Followed by Autologous Hematopoietic Stem Cell Infusion in Refractory Lymphoma: A Study of Feasibility and Efficacy
214. Impact on Progression Free Survival of Autologous Stem Cell transplantation after Consolidation with Alemtuzumab in Chronic Lymphocytic Leukemia.
215. Results of a Phase II Multicenter Study of Immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Symptomatic Waldenstrom’s Macroglobulinemia
216. Coexistence of Trisomy 8 as Both Clonal and Adjunctive Cytogenetic Abnormality in Philadelphia-Positive (Ph+) Chronic Myeloid Leukemia (CML) Patients on Treatment with Tirosine Kinase Inhibitors (TKIs): Report of Two Cases
217. Utility of FDG-PET in Post Transplant Lymphoproliferative Disorders: An Update from a Single Center Experience
218. Laparoscopic Splenectomy for Immune Thrombocytopenic Purpura (ITP): A Single Center Experience
219. Multicentric Clinical Audit of Chemotherapy Administration for Lymphoprolipherative Diseases in Day Hospital Patient Setting
220. A New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment
221. Imatinib Long Term Effects (ILTE) Study: An Independent, International Study in CML Patients.
222. Prognostic value of circulating CD34+ cells in myelodysplastic syndromes
223. Prospective monocentric study of non-tunnelled central venous catheter-related complications in hematological patients
224. Prevalence and Prognostic Impact of KIT Mutations in Acute Myeloid Leukaemia with Inv(16). A Retrospective Study.
225. Fludarabine, Cyclophosphamide and Rituximab in Waldenström’s Macroglobulinemia: An Effective Regimen Requiring a New Category of Response Criteria and a Delayed Assessment of Results
226. Management of High Haemorragic Risk Surgery: A Case of Acquired von Willebrand Disease (AVWD).
227. Prognostic Significance of CD33, CD34 and CD117 Expression on Bone Marrow Blasts of Patients with Myelodysplastic Syndromes.
228. Skeletal Involvement in Advanced Stage Lymphomas: Role of Total Body Magnetic Resonance.
229. A Dynamic Prognostic Model To Predict Survival in Post-Polycythemia Vera Myelofibrosis.
230. Real-Life Rates of Disease Monitoring in Clinical Practice in Europe: The “Unmet Needs in CML and Ph+ALL” (UNIC) Study.
231. Transient Massive Lymphoid Bone Marrow Infiltrate Developing during Therapy with the Tyrosine Kinase Inhibitors Imatinib and Nilotinib: Report of 2 Patients.
232. Imatinib Resistance and/or Intolerance in Clinical Practice in Europe: The “Unmet Needs in CML and Ph+ALL” (UNIC) Study.
233. Bortezomib with HIG-Dose Dexamethasone as First Line Therapy in Patients with Multiple Myeloma Candidates to High-Dose Therapy.
234. Combined Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC), an Active Regimen for Treated Patients with Chronic Lymphocytic Leukemia (CLL).
235. Intermediate Dose Ara-C Followed by G-CSF: An Effective and Predictable Mobilization Regimen in Hematological Malignancies.
236. Flow Cytometric Examination of Non-Hematic Body Fluids in Hematologic Malignancies: A Comparison with Cytology.
237. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation
238. Portal Vein Thrombosis Following Splenectomy for Hematologic Diseases: Prevalence and Risk Factors.
239. Oxaliplatin as Single Agent or in Combination in Chronic Lymphocytic Leukaemia (CLL).
240. Intense Reversal of Bone Marrow Angiogenesis after Consolidation Therapy with Alemtuzumab in Advanced Chronic Lymphocytic Leukemia.
241. Low Efficacy of Thalidomide in Improving Response after Induction in Myeloma Patients Candidate to High-Dose Therapy.
242. Clinical Features and Prognostic Assessment of Nodal Marginal Zone B-Cell Lymphoma, a Rare Disease with Follicular-Like Behaviour.
243. Serum Tryptase Levels in AML at Diagnosis: A Multicenter Retrospective Study.
244. Analysis of immunoglobulin heavy and light chain variable genes in post‐transplant lymphoproliferative disorders
245. Nongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination
246. Pharmacokinetic Behavior of Rituximab
247. Pharmacokinetic Analysis of Subcutaneous Alemtuzumab as Consolidation Therapy To Achieve MRD-Negative Responses.
248. Purging "In Vivo" with Alemtuzumab (Campath-1H) before Autologous Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).
249. Obesity Independently Predicts Event Free Survival (EFS) in Adults with BCR-ABL-Negative Acute Lymphoblastic Leukemia (ALL). A Retrospective Analysis of Two GIMEMA Studies.
250. Molecular Analysis of Posttransplant Lymphoproliferative Disorders (PTLD) of Donor Origin Occuring in Liver Transplant Patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.